Identification of hydroxyanthraquinones as novel inhibitors of hepatitis C Virus NS3 helicase

International Journal of Molecular Sciences

Volumn 16, Issue 8, 2015, Pages 18439-18453

  Furuta, Atsushi ^a,b   Tsubuki, Masayoshi ^c   Endoh, Miduki ^c   Miyamoto, Tatsuki ^a,b   Tanaka, Junichi ^d   Salam, Kazi Abdus ^e   Akimitsu, Nobuyoshi ^e   Tani, Hidenori ^b   Yamashita, Atsuya ^f   Moriishi, Kohji ^f   Nakakoshi, Masamichi ^g   Sekiguchi, Yuji ^b   Tsuneda, Satoshi ^a   Noda, Naohiro ^a,b  

^a WASEDA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c HOSHI UNIVERSITY   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f UNIVERSITY OF YAMANASHI   (Japan)

^g TOHO UNIVERSITY   (Japan)

Author keywords

Fluorescence resonance energy transfer; Hepatitis C virus; Hydroxyanthraquinone; Hypericin; Inhibitor; NS3 helicase; Sennidin A

Indexed keywords

ANTHRAQUINONE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; HYPERICIN; MITOXANTRONE; NOGALAMYCIN; NONSTRUCTURAL PROTEIN 3; PLANT MEDICINAL PRODUCT; SENNIDIN A; UNCLASSIFIED DRUG; 1,4,5,8-TETRAHYDROXYANTHRAQUINONE; ANTHRACENE DERIVATIVE; ANTIVIRUS AGENT; DIHYDROXYDIANTHRONE; NS3 PROTEIN, HEPATITIS C VIRUS; PERYLENE; RNA HELICASE; VIRAL PROTEIN;

ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; EC50; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC50; NONHUMAN; OPEN READING FRAME; PROTEIN EXPRESSION; PROTEIN MULTIMERIZATION; VIRUS MUTATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HEPACIVIRUS; HEPATITIS C; METABOLISM; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; VIROLOGY;

HEPATITIS C VIRUS;

ANTHRACENES; ANTHRAQUINONES; ANTIVIRAL AGENTS; CELL LINE; HEPACIVIRUS; HEPATITIS C; HUMANS; PERYLENE; RNA HELICASES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84938901961     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160818439     Document Type: Article

References (51)

1. Marcellin, P.; Asselah, T.; Boyer, N. Fibrosis and disease progression in hepatitis C. Hepatology 2002, 36, S47-S56.
2. Ghany, M.G.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49, 1335-1374.
3. Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.; Albrecht, J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001, 358, 958-965.
4. Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; Smith, C.; Marinos, G.; Gonçales, F.L.; Häussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347, 975-982.
5. Bartenschlager, R.; Lohmann, V.; Penin, F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 2013, 11, 482-496.
6. Poordad, F.; McCone, J.; Bacon, B.R.; Bruno, S.; Manns, M.P.; Sulkowski, M.S.; Jacobson, I.M.; Reddy, K.R.; Goodman, Z.D.; Boparai, N.; et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364, 1195-1206.
7. Hézode, C.; Forestier, N.; Dusheiko, G.; Ferenci, P.; Pol, S.; Goeser, T.; Bronowicki, J.-P.; Bourlière, M.; Gharakhanian, S.; Bengtsson, L.; et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009, 360, 1839-1850.
8. Ghany, M.G.; Nelson, D.R.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54, 1433-1444.
9. Lawitz, E.; Poordad, F.F.; Pang, P.S.; Hyland, R.H.; Ding, X.; Mo, H.; Symonds, W.T.; McHutchison, J.G.; Membreno, F.E. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014, 383, 515-523.
10. Afdhal, N.; Zeuzem, S.; Kwo, P.; Chojkier, M.; Gitlin, N.; Puoti, M.; Romero-Gomez, M.; Zarski, J.-P.; Agarwal, K.; Buggisch, P.; et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 2014, 370, 1889-1898.
11. Kowdley, K.V.; Gordon, S.C.; Reddy, K.R.; Rossaro, L.; Bernstein, D.E.; Lawitz, E.; Shiffman, M.L.; Schiff, E.; Ghalib, R.; Ryan, M.; et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014, 370, 1879-1888.
12. Afdhal, N.; Reddy, K.R.; Nelson, D.R.; Lawitz, E.; Gordon, S.C.; Schiff, E.; Nahass, R.; Ghalib, R.; Gitlin, N.; Herring, R.; et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 2014, 370, 1483-1493.
13. Jo, Y.M.; Lee, S.W.; Han, S.Y.; Baek, Y.H.; Kim, S.Y.; Kim, W.J.; Ahn, J.H.; Lee, J.Y. Retreatment with peginterferon and ribavirin in chronic hepatitis C. World J. Gastroenterol. 2015, 21, 1994-1999.
14. Choo, Q.L.; Kuo, G.; Weiner, A.J.; Overby, L.R.; Bradley, D.W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244, 359-362.
15. Bartenschlager, R.; Penin, F.; Lohmann, V.; André, P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011, 19, 95-103.
16. Gallinari, P.; Brennan, D.; Nardi, C.; Brunetti, M.; Tomei, L.; Steinkühler, C.; de Francesco, R. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J. Virol. 1998, 72, 6758-6769.
17. Kim, D.W.; Gwack, Y.; Han, J.H.; Choe, J. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem. Biophys. Res. Commun. 1995, 215, 160-166.
18. Tai, C.L.; Chi, W.K.; Chen, D.S.; Hwang, L.H. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J. Virol. 1996, 70, 8477-8484.
19. Gwack, Y.; Kim, D.W.; Han, J.H.; Choe, J. Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein. Biochem. Biophys. Res. Commun. 1996, 225, 654-659.
20. Gwack, Y.; Kim, D.W.; Han, J.H.; Choe, J. DNA helicase activity of the hepatitis C virus nonstructural protein 3. Eur. J. Biochem. 1997, 250, 47-54.
21. Lam, A.M.I.; Frick, D.N. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J. Virol. 2006, 80, 404-411.
22. Kolykhalov, A.A.; Mihalik, K.; Feinstone, S.M.; Rice, C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74, 2046-2051.
23. Kwong, A.D.; Rao, B.G.; Jeang, K.-T. Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov. 2005, 4, 845-853.
24. Borowski, P.; Schalinski, S.; Schmitz, H. Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy. Antivir. Res. 2002, 55, 397-412.
25. Krawczyk, M.; Wasowska-Lukawska, M.; Oszczapowicz, I.; Boguszewska-Chachulska, A.M. Amidinoanthracyclines-A new group of potential anti-hepatitis C virus compounds. Biol. Chem. 2009, 390, 351-360.
26. Tani, H.; Fujita, O.; Furuta, A.; Matsuda, Y.; Miyata, R.; Akimitsu, N.; Tanaka, J.; Tsuneda, S.; Sekiguchi, Y.; Noda, N. Real-time monitoring of RNA helicase activity using fluorescence resonance energy transfer in vitro. Biochem. Biophys. Res. Commun. 2010, 393, 131-136.
27. Furuta, A.; Salam, K.A.; Tani, H.; Tsuneda, S.; Sekiguchi, Y.; Akimitsu, N.; Noda, N. A fluorescence-based screening assay for identification of hepatitis C virus NS3 helicase inhibitors and characterization of their inhibitory mechanism. Methods Mol. Biol. 2015, 1259, 211-228.
28. El Ezaby, M.S.; Salem, T.M.; Zewail, A.H.; Issa, R. Spectral studies of some hydroxy-derivatives of anthraquinones. J. Chem. Soc. B 1970, 7, 1293-1296.
29. Furuta, A.; Salam, K.A.; Hermawan, I.; Akimitsu, N.; Tanaka, J.; Tani, H.; Yamashita, A.; Moriishi, K.; Nakakoshi, M.; Tsubuki, M.; et al. Identification and biochemical characterization of halisulfate 3 and suvanine as novel inhibitors of hepatitis C virus NS3 helicase from a marine sponge. Mar. Drugs 2014, 12, 462-476.
30. Zhang, J.H.; Chung, T.D.; Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4, 67-73.
31. Fain, V.Y.; Zaitsev, B.E.; Ryabov, M.A. A quantum-chemical and correlation study of ionization of α,α′-dihydroxyanthraquinones. Russ. J. Gen. Chem. 2003, 73, 1925-1931.
32. Fain, V.Y.; Zaitsev, B.E.; Ryabov, M.A. Metal complexes with 1-hydroxyanthraquinone and its derivatives: Electronic absorption spectra and ligand structures. Russ. J. Coord. Chem. 2006, 32, 610-613.
33. Hilgert, I.; Cudlín, J.; Steinerová, N.; Vanĕk, Z. Antitumour and immunosuppressive activity of hydroxyanthraquinones and their glucosides. Folia Biol. (Praha) 1977, 23, 99-109.
34. Tikkanen, L.; Matsushima, T.; Natori, S. Mutagenicity of anthraquinones in the Salmonella preincubation test. Mutat. Res. 1983, 116, 297-304.
35. Kawai, K.; Mori, H.; Sugie, S.; Yoshimi, N.; Inoue, T.; Nakamaru, T.; Nozawa, Y.; Matsushima, T. Genotoxicity in the hepatocyte/DNA repair test and toxicity to liver mitochondria of 1-hydroxyanthraquinone and several dihydroxyanthraquinones. Cell Biol. Toxicol. 1986, 2, 457-467.
36. Mori, H.; Yoshimi, N.; Iwata, H.; Mori, Y.; Hara, A.; Tanaka, T.; Kawai, K. Carcinogenicity of naturally occurring 1-hydroxyanthraquinone in rats: Induction of large bowel, liver and stomach neoplasms. Carcinogenesis 1990, 11, 799-802.
37. Mori, Y.; Yoshimi, N.; Iwata, H.; Tanaka, T.; Mori, H. The synergistic effect of 1-hydroxyanthraquinone on methylazoxymethanol acetate-induced carcinogenesis in rats. Carcinogenesis 1991, 12, 335-338.
38. Tanaka, T.; Kojima, T.; Yoshimi, N.; Sugie, S.; Mori, H. Inhibitory effect of the non-steroidal anti-inflammatory drug, indomethacin on the naturally occurring carcinogen, 1-hydroxyanthraquinone in male ACI/N rats. Carcinogenesis 1991, 12, 1949-1952.
39. Mori, H.; Ohnishi, M.; Kawamori, T.; Sugie, S.; Tanaka, T.; Ino, N.; Kawai, K. Toxicity and tumorigenicity of purpurin, a natural hydroxanthraquinone in rats: Induction of bladder neoplasms. Cancer Lett. 1996, 102, 193-198.
40. Kuo, D.H.; Kuo, S.C.; Cheng, J.T. Structure-activity relationships of anthraquinones in the decrease of intestinal motility. J. Pharm. Pharmacol. 2000, 52, 839-841.
41. Fotia, C.; Avnet, S.; Granchi, D.; Baldini, N. The natural compound Alizarin as an osteotropic drug for the treatment of bone tumors. J. Orthop. Res. 2012, 30, 1486-1492.
42. Shadrick, W.R.; Mukherjee, S.; Hanson, A.M.; Sweeney, N.L.; Frick, D.N. Aurintricarboxylic acid modulates the affinity of hepatitis C virus NS3 helicase for both nucleic acid and ATP. Biochemistry 2013, 52, 6151-6159.
43. Karioti, A.; Bilia, A.R. Hypericins as potential leads for new therapeutics. Int. J. Mol. Sci. 2010, 11, 562-594.
44. Abe, D.; Saito, T.; Sekiya, K. Sennidin stimulates glucose incorporation in rat adipocytes. Life Sci. 2006, 79, 1027-1033.
45. Ji, Y.; Jiang, C.; Zhang, X.; Liu, W.; Gao, M.; Li, Y.; Wang, J.; Wang, Q.; Sun, Z.; Jiang, X.; et al. Necrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models. Oncotarget 2014, 5, 2934-2946.
46. Belon, C.A.; Frick, D.N. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol. 2009, 4, 277-293.
47. Norvez, S. Liquid crystalline triptycene derivatives. J. Org. Chem. 1993, 58, 2414-2418.
48. Tani, H.; Akimitsu, N.; Fujita, O.; Matsuda, Y.; Miyata, R.; Tsuneda, S.; Igarashi, M.; Sekiguchi, Y.; Noda, N. High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon. Biochem. Biophys. Res. Commun. 2009, 379, 1054-1059.
49. Copeland, R.A. Lead optimization and structure-activity relationships for reversible inhibitors. In Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists; Copeland, R.A., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2005; pp. 111-140.
50. Furuta, A.; Salam, K.A.; Akimitsu, N.; Tanaka, J.; Tani, H.; Yamashita, A.; Moriishi, K.; Nakakoshi, M.; Tsubuki, M.; Sekiguchi, Y.; et al. Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase. J. Enzym. Inhib. Med. Chem. 2014, 29, 223-229.
51. Yokota, T.; Sakamoto, N.; Enomoto, N.; Tanabe, Y.; Miyagishi, M.; Maekawa, S.; Yi, L.; Kurosaki, M.; Taira, K.; Watanabe, M.; et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003, 4, 602-608.